DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Ambroxol is an investigational drug.
There have been 21 clinical trials for Ambroxol. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2005.
The most common disease conditions in clinical trials are Pharyngitis, Parkinson Disease, and Gaucher Disease. The leading clinical trial sponsors are Boehringer Ingelheim, Sanofi, and Hyundai Pharmaceutical Co., LTD.
Recent Clinical Trials for Ambroxol
|A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respirator||Zambon SpA||Phase 3|
|Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy||Shaare Zedek Medical Center||Phase 2|
|Efficacy and Safety Study of New Ambroxol Hardboiled Lozenges in Acute Pharyngitis||Sanofi||Phase 3|